Shanghai Hile Bio-tech (603718) - Total Liabilities
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has total liabilities worth CN¥408.00 Million CNY (≈ $59.70 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shanghai Hile Bio-tech long-term investment intensity to see how much of total assets are deployed in long-term investments.
Shanghai Hile Bio-tech - Total Liabilities Trend (2011–2025)
This chart illustrates how Shanghai Hile Bio-tech's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 603718 current and non-current assets.
Shanghai Hile Bio-tech Competitors by Total Liabilities
The table below lists competitors of Shanghai Hile Bio-tech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Profit Cultural & Creative Group Co Ltd
SHE:300640
|
China | CN¥323.69 Million |
|
Jouder Precision Industry Kunshan Co Ltd
SHE:300549
|
China | CN¥161.08 Million |
|
Fabryka Farb i Lakierów ŚNIEŻKA SA
WAR:SKA
|
Poland | zł289.79 Million |
|
Stove Kraft Limited
NSE:STOVEKRAFT
|
India | Rs6.70 Billion |
|
Pan Malaysia Holdings Bhd
KLSE:1287
|
Malaysia | RM156.57 Million |
|
Text S.A.
WAR:TXT
|
Poland | zł96.26 Million |
|
Dongsung FineTec Co. Ltd
KQ:033500
|
Korea | ₩224.84 Billion |
|
Taiga Building Products Ltd.
TO:TBL
|
Canada | CA$284.53 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Shanghai Hile Bio-tech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 603718 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Hile Bio-tech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Hile Bio-tech (2011–2025)
The table below shows the annual total liabilities of Shanghai Hile Bio-tech from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥229.14 Million ≈ $33.53 Million |
+85.32% |
| 2024-12-31 | CN¥123.65 Million ≈ $18.09 Million |
-74.40% |
| 2023-12-31 | CN¥482.96 Million ≈ $70.67 Million |
+19.77% |
| 2022-12-31 | CN¥403.25 Million ≈ $59.01 Million |
-52.94% |
| 2021-12-31 | CN¥856.90 Million ≈ $125.39 Million |
+3.92% |
| 2020-12-31 | CN¥824.54 Million ≈ $120.66 Million |
+16.34% |
| 2019-12-31 | CN¥708.72 Million ≈ $103.71 Million |
-1.95% |
| 2018-12-31 | CN¥722.81 Million ≈ $105.77 Million |
+37.20% |
| 2017-12-31 | CN¥526.83 Million ≈ $77.09 Million |
+11.02% |
| 2016-12-31 | CN¥474.55 Million ≈ $69.44 Million |
+71.31% |
| 2015-12-31 | CN¥277.01 Million ≈ $40.54 Million |
+188.62% |
| 2014-12-31 | CN¥95.98 Million ≈ $14.04 Million |
-4.19% |
| 2013-12-31 | CN¥100.17 Million ≈ $14.66 Million |
+7.97% |
| 2012-12-31 | CN¥92.78 Million ≈ $13.58 Million |
-5.61% |
| 2011-12-31 | CN¥98.29 Million ≈ $14.38 Million |
-- |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The company offers biochemistry reagents, immunoturbidimetric latex reagents, immune turbidimetry reagents, latex enhanced … Read more